It's a shame it has been hi-jacked by trolls! Perhaps one day, the good old days might return?
Have a good one, guys! Patience is a virtue!!
Did you catch the video of his father speaking to his son in Pashto? He said that it might take him awhile to "return" to his language? Seriously? And, WHO walks off a base in the middle of a war zone? 5 TOP Taliban? Most incompetent president in my lifetime!!
It's called "wishful thinking" for their short friends. As suspected, they probably added to their shorts on the rise yesterday thinking they'd have "their way" with the stock today. 4 more million traded this morning above $6 ... I call that consolidation/accumulation ... soon to be followed by COVERING?
Good post ...
I NEVER respond to that trash and use the ignore/report feature very generously. Why Yahoo doesn't do something about this is beyond me. It definitely has gotten worse across all boards. This one has always been kind of a cesspool for these creatures!
Have a good weekend!
WHO writes an article like that 60 minutes into a trading day? Down "BIG"? Even if it only consolidated yesterday's move, it hardly qualifies as a "reversal"! The only reversal that clown is going to see is the one where HK just went green!!
Undoubtedly, we have some NEW short friends at these levels. More fuel for the "Barbie"!!
Have a great day!
the market cap is ridiculously low for this company right here. Look at some others in the biotech space with NO revenue, P1 or P2 trials and compare them to where NBS is now. Do the math ... and buy the dips!!
Have a great day!
Dumped it after some loss. It got tied up in politics; it's the government, after all!! All wrapped in a court case, to boot. I'm big into a couple of stem cell companies for the past couple of years. It's the medical wave of the future ... (hint, hint)!!
Do you still own it? Unfortunately, I "took profits" around $12 and never looked back because it makes me sick! ;-)
NeoStem is initiating a Phase 3 study of Melapuldencel-T later this year under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration, and the therapy has been granted fast-track designation by the agency as well
"Did anyone at ACRX ever do any research into the real world of post operative patient care? It appears not."
Yup, you're absolutely correct, Pentech! Millions spent on developing their product, but not one thought given to the "real world" of post operative care! WHAT were they thinking? You're a genius, man ... sheer genius!!!
NeoStem presents five-year survival data for autologous melanoma Immunotherapy
NeoStem announced results of a pooled analysis indicating that Melapuldencel-T, an investigational patient-specific immunotherapy for metastatic melanoma, may increase survival rates significantly for patients at the most advanced stages of the disease. The findings will be presented on Sunday, June 1 in a poster by Robert O. Dillman, MD, study author and Vice-President, NeoStem Oncology, at the 50th Annual Meeting of the American Society of Clinical Oncology, or ASCO. The analysis to be presented at ASCO includes a subset of pooled data from three melanoma clinical trials, conducted successively from 1990-2011. Two of these trials, one of which was controlled and one of which was not, studied Melapuldencel-T. The new pooled analysis indicates significantly better five-year overall survival rates in patients treated with Melapuldencel-T than those treated with the comparator therapy for the subset of patients who still had evidence of disease after prior treatment with one or more standard therapies. "This subset analysis lends further support to the view that tumor-initiating cells are viable targets for therapeutic interventions like Melapuldencel-T, aiming for better overall survival, even for patients in the most advanced stages of malignant melanoma. In addition, the product may have significant safety and tolerability advantages over existing therapies," said Dr. Dillman. Chief Medical Officer Douglas Losordo, said, "NeoStem is excited to continue investigating this promising therapy in a large-scale Phase 3 study beginning this year." Melapuldencel-T was developed by California Stem Cell, Inc., which was acquired by NeoStem in May. NeoStem is initiating a Phase 3 study of Melapuldencel-T later this year under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration, and the therapy has been granted fast-track designation by the agency as well.
It's really ALL speculation, but the cynic in me tells me it is manipulation, albeit a lot of money spent to create the illusion of "profit-taking" from our recent run up. In the face of positive news and no real market sell-off, I saw it as a means to accumulate some shares all day (like we are seeing) at a lower price. It's all good because once the accumulation ends, we go higher based on improving fundamentals.
The REAL trick, bnytch, is to KNOW what you own so that you don't get shaken out by those kinds of moves. The most blatant move was when they took it below $5. If it doesn't make sense when that happens, just take a deep breath and add to your position, even if those shares are simply a trade.
Good luck ... being confident in where you are and letting the story play out is the key.
Wouldn't you love to know "who" felt the need to dump 80,000+ shares at the open this a.m. on the heels of an upgrade and announcement of a new client? Um hmmmmmm ....
Got that alert this a.m., too, G ... In fact, I added on the orchestrated take-down after the open, too, based on a new customer and the "speculative buy" issued this a.m. This is soooo under the radar!!!